Fulfilling the promise of the 2015 Paris Agreement on climate
change—most notably the goal of limiting the rise in mean global surface
temperature since preindustrial times to 2 degrees Celsius—will require
a dramatic transition away from fossil fuels and toward low-carbon
energy sources. To map out that transition, decision-makers routinely
turn to energy scenarios, which use computational models to project
changes to the energy mix that will be needed to meet climate and
environmental targets. These models account for not only technological,
economic, demographic, political, and institutional developments, but
also the scope, timing, and stringency of policies to reduce greenhouse
gas emissions and air pollution.
Credit: David Pilbrow/Flickr
Model-driven energy
scenarios provide policymakers and investors with a powerful
decision-support tool but should not be used as a decision-making tool
due to several limitations. So argues a new study in the journal Energy
and Environment by Sergey Paltsev, deputy director of the MIT Joint
Program on the Science and Policy of Global Change and a senior research
scientist for both the Joint Program and the MIT Energy Initiative. The
study shows that overall, energy scenarios are useful for assessing
policymaking and investment risks associated with different emissions
reduction pathways, but tend to overestimate the degree to which future
energy demand will resemble the past.
"Energy scenarios may not provide exact projections, but they are the
best available tool to assess the magnitude of challenges that lie
ahead," Paltsev observes in the study, a unique review of the value and
limits of widely used energy scenarios that range from the International
Energy Agency (IEA) World Energy Outlook, to the Joint Program's own annual Food, Water, Energy and Climate Outlook (which uses the MIT Economic Projection and Policy Analysis model), to a recent Intergovernmental Panel on Climate Change (IPCC) assessment report (AR5) presenting 392 energy scenarios aligned with the 2 C climate stabilization goal.
The study points out that because energy scenarios tend to vary
widely in terms of the projections they produce for a given policy and
the degree of uncertainty associated with those projections, it's not
advisable to base an energy policy or investment decision on a single
energy scenario. Taken collectively, however, energy scenarios can help
bring into sharp focus a range of plausible futures—information
decision-makers can use to assess the scale and cost of the
technological changes needed to effect significant transformations in
energy production and consumption. A careful review of multiple energy
scenarios associated with a particular emissions pathway can provide a
qualitative analysis of what's driving the results and the potential
risks and benefits of a proposed policy or investment.
That said, projections in energy scenarios can sometimes be highly inaccurate due to factors that are difficult to anticipate.
For example, according to the study, which compared several energy
scenario projections to historical observations, most energy scenarios
do not account for sudden changes to the status quo. One of the greatest
contributors to uncertainty in energy scenarios is the demand for
low-emitting energy technologies, whose timing and scale of
deployment—dependent on several economic and political factors—is highly
unpredictable. Paltsev notes that the IEA constantly underestimates renewable energy production;
in its 2006 World Energy Outlook, the agency projected for 2020 a level
of wind power generation that the world exceeded as early as 2013.
In addition, while energy scenarios have been largely successful in projecting the quantity of global energy demand
(e.g., the 1994 IEA World Energy Outlook's projection for 2010 was off
by only 10 percent, despite highly disruptive developments such as the
breakup of the Soviet Union, the world recession in 2008, and the
emergence of the shale gas industry), most have been considerably off
the mark when it comes to projecting energy prices (e.g., in 1993
dollars, the 1994 IEA WEO projected $28/barrel in 2010, but the actual
price was $53/barrel).
Recognizing the steep challenge in projecting demand and prices for
different energy sources in the midst of a dramatic energy transition,
Paltsev emphasizes that governments should not try to pick a "winner"—a
single energy technology that seems poised to reduce emissions
singlehandedly—but rather adopt a strategy that targets emissions
reductions from any energy source.
"Governments shouldn't pick the winners, because most likely that
choice will be wrong," he says. "They should instead design policies
such as carbon-pricing and emissions trading systems that are designed
to achieve emissions reduction targets at the least cost."
A gene known to suppress tumor
formation in a broad range of tissues plays a key role in keeping stem
cells in muscles dormant until needed, a finding that may have
implications for both human health and animal production, according to a
Purdue University study.
Shihuan Kuang,
professor of animal sciences, and Feng Yue, a postdoctoral researcher in
Kuang's lab, reported their findings in two papers published in the
journals Cell Reports and Nature Communications. The results suggest modifying expression of the PTEN gene could one day play a role in increasing muscle mass in agricultural animals and improve therapies for muscle injuries in humans.
Muscle stem cells, called satellite cells,
normally sit in a quiescent, or dormant, state until called upon to
build muscle or repair a damaged muscle. Inability to maintain the
quiescence would lead to a loss of satellite cells. As humans age, the
number of satellite cells gradually declines and the remaining cells
become less effective in regenerating muscles, resulting in muscle loss –
a condition called sarcopenia.
Kuang and Yue, in the Nature Communications paper, explored
the role tumor-suppressor gene PTEN plays in satellite cells. The PTEN
gene encodes a protein that suppresses the growth signaling, thereby,
limiting the growth of fast-growing tumor cells. Mutation of the PTEN
gene is associated with many types of cancers, but how the gene
functions in muscle stem cells is unknown.
To understand the function of a gene, the authors first wanted to know how the gene is expressed.
"This gene is highly expressed in the satellite cells when the cells
are in the quiescent state. When they become differentiated, the PTEN
level reduces," Yue said.
By knocking out the PTEN gene in resting satellite cells, the
researchers found that satellite cells quickly differentiate and become muscle cells. So PTEN plays an essential role in keeping satellite cells in their quiescent state.
"You no longer have the stem cells once you knock out the gene," Kuang said.
In their Cell Reports paper, Kuang and Yue took a step further
to examine PTEN function in proliferating stem cells. This time, they
knocked out PTEN in embryonic progenitor cells, those that will later
become muscle in the mouse. They found that as the mouse grew, muscle
mass increased significantly—by as much as 40 percent in some
muscles—over that of a normal mouse.
"That would be significant in an animal production point of view," Kuang said.
The increased muscle came with a cost, however. Besides creating muscle, those progenitor cells
create satellite cells. Without PTEN, not only fewer satellite cells
were created, but the resulting satellite cells cannot maintain
dormancy, leading to an accelerated rate of depletion during aging.
The faster depletion of satellite cells during aging wouldn't matter
much in an animal production scenario, Kuang said. Beef cattle, for
example, are harvested before they age. The increase in muscle mass,
however, would be a significant advantage in production efficiency.
The findings may lead to improvement in human health, the authors
said. The ability to control the expression of PTEN could lead to
therapies for quicker healing of muscle injuries.
"If you want to quickly boost up the stem cells to repair something,
you need to suppress PTEN," Kuang said. "After that, you'd need to
increase PTEN to return the cells back to quiescent state. If we could
do that, you would suspect that the muscle would repair more quickly."
Knowing that PTEN also suppresses tumors in many types of tissues,
the authors noted that the elimination of the gene did not cause tumor
formation in the muscle
cells they studied. That suggests regulation of PTEN could be a
feasible method for improving human health and animal agriculture.
Researchers at the University of California San Diego
investigate why hair is incredibly strong and resistant to breaking.
Credit: iStock.com/natevplas
In a new study, researchers at the
University of California San Diego investigate why hair is incredibly
strong and resistant to breaking. The findings could lead to the
development of new materials for body armor and help cosmetic
manufacturers create better hair care products.
Hair has a
strength to weight ratio comparable to steel. It can be stretched up to
one and a half times its original length before breaking. "We wanted to
understand the mechanism behind this extraordinary property," said Yang
(Daniel) Yu, a nano-engineering Ph.D. student at UC San Diego and the
first author of the study.
"Nature creates a variety of interesting materials and architectures
in very ingenious ways. We're interested in understanding the
correlation between the structure and the properties of biological
materials to develop synthetic materials and designs—based on
nature—that have better performance than existing ones," said Marc
Meyers, a professor of mechanical engineering at the UC San Diego Jacobs
School of Engineering and the lead author of the study.
In a study published online in Dec. in the journal Materials Science and Engineering C, researchers examined at the nano-scale level how a strand of human hair
behaves when it is deformed, or stretched. The team found that hair
behaves differently depending on how fast or slow it is stretched. The
faster hair is stretched, the stronger it is. "Think of a highly viscous
substance like honey," Meyers explained. "If you deform it fast it
becomes stiff, but if you deform it slowly it readily pours."
Hair consists of two main parts—the cortex, which is made up of
parallel fibrils, and the matrix, which has an amorphous (random)
structure. The matrix is sensitive to the speed at which hair is
deformed, while the cortex is not. The combination of these two
components, Yu explained, is what gives hair the ability to withstand
high stress and strain.
And as hair is stretched, its structure changes in a particular way.
At the nano-scale, the cortex fibrils in hair are each made up of
thousands of coiled spiral-shaped chains of molecules called alpha helix
chains. As hair is deformed, the alpha helix chains uncoil and become
pleated sheet structures known as beta sheets. This structural change
allows hair to handle up a large amount deformation without breaking.
This structural transformation is partially reversible. When hair is
stretched under a small amount of strain, it can recover its original
shape. Stretch it further, the structural transformation becomes
irreversible. "This is the first time evidence for this transformation
has been discovered," Yu said.
"Hair is such a common material with many fascinating properties,"
said Bin Wang, a UC San Diego PhD alumna and co-author on the paper.
Wang is now at the Shenzhen Institutes of Advanced Technology in China
continuing research on hair.
The team also conducted stretching tests on hair at different
humidity levels and temperatures. At higher humidity levels, hair can
withstand up to 70 to 80 percent deformation before breaking. Water
essentially "softens" hair—it enters the matrix and breaks the sulfur
bonds connecting the filaments inside a strand of hair. Researchers also
found that hair starts to undergo permanent damage at 60 degrees
Celsius (140 degrees Fahrenheit). Beyond this temperature, hair breaks
faster at lower stress and strain.
"Since I was a child I always wondered why hair is so strong. Now I
know why," said Wen Yang, a former postdoctoral researcher in Meyers'
research group and co-author on the paper.
The team is currently conducting further studies on the effects of water on the properties of human hair.
Moving forward, the team is investigating the detailed mechanism of how
washing hair causes it to return to its original shape.
In a light harvesting quantum photocell, particles of light
(photons) can efficiently generate electrons. When two absorbing
channels are used, solar power entering the system through the two
absorbers (a and b) efficiently generates power …more
A
University of California, Riverside assistant professor has combined
photosynthesis and physics to make a key discovery that could help make
solar cells more efficient. The findings were recently published in the
journal Nano Letters.
Nathan Gabor
is focused on experimental condensed matter physics, and uses light to
probe the fundamental laws of quantum mechanics. But, he got interested
in photosynthesis when a question popped into his head in 2010: Why are
plants green? He soon discovered that no one really knows.
During the past six years, he sought to help change that by combining his background in physics with a deep dive into biology.
He set out to re-think solar energy conversion
by asking the question: can we make materials for solar cells that more
efficiently absorb the fluctuating amount of energy from the sun.
Plants have evolved to do this, but current affordable solar cells -
which are at best 20 percent efficient - do not control these sudden
changes in solar power, Gabor said. That results in a lot of wasted
energy and helps prevent wide-scale adoption of solar cells as an energy
source.
Gabor, and several other UC Riverside physicists, addressed the problem by designing a new type of quantum heat engine photocell, which helps manipulate the flow of energy in solar cells.
The design incorporates a heat engine photocell that absorbs photons
from the sun and converts the photon energy into electricity.
Surprisingly, the researchers found that the quantum heat engine
photocell could regulate solar power conversion without requiring active
feedback or adaptive control mechanisms. In conventional photovoltaic
technology, which is used on rooftops and solar farms today,
fluctuations in solar power must be suppressed by voltage converters and
feedback controllers, which dramatically reduce the overall efficiency.
Nathan Gabor's Laboratory of Quantum Materials Optoelectronics
utilizes infrared laser spectroscopy techniques to explore natural
regulation in quantum photocells composed of two-dimensional
semiconductors. Credit: Max Grossnickle and QMO Lab
The goal of the UC Riverside teams was to
design the simplest photocell that matches the amount of solar power
from the sun as close as possible to the average power demand and to
suppress energy fluctuations to avoid the accumulation of excess energy.
The researchers compared the two simplest quantum mechanical
photocell systems: one in which the photocell absorbed only a single
color of light, and the other in which the photocell absorbed two
colors. They found that by simply incorporating two photon-absorbing
channels, rather than only one, the regulation of energy flow emerges
naturally within the photocell.
The basic operating principle is that one channel absorbs at a
wavelength for which the average input power is high, while the other
absorbs at low power. The photocell switches between high and low power
to convert varying levels of solar power into a steady-state output.
When Gabor's team applied these simple models to the measured solar
spectrum on Earth's surface, they discovered that the absorption of
green light, the most radiant portion of the solar power
spectrum per unit wavelength, provides no regulatory benefit and should
therefore be avoided. They systematically optimized the photocell
parameters to reduce solar energy fluctuations, and found that the
absorption spectrum looks nearly identical to the absorption spectrum
observed in photosynthetic green plants.
The findings led the researchers to propose that natural regulation
of energy they found in the quantum heat engine photocell may play a
critical role in the photosynthesis in plants, perhaps explaining the
predominance of green plants on Earth.
Other researchers have recently found that several molecular
structures in plants, including chlorophyll a and b molecules, could be
critical in preventing the accumulation of excess energy
in plants, which could kill them. The UC Riverside researchers found
that the molecular structure of the quantum heat engine photocell they
studied is very similar to the structure of photosynthetic molecules
that incorporate pairs of chlorophyll.
The hypothesis set out by Gabor and his team is the first to connect
quantum mechanical structure to the greenness of plants, and provides a
clear set of tests for researchers aiming to verify natural regulation.
Equally important, their design allows regulation without active input, a
process made possible by the photocell's quantum mechanical structure.
The paper is called "Natural Regulation of Energy Flow in a Green Quantum Photocell.
A breakthrough in solar power could make it cheaper and more
commercially viable, thanks to research at the University of Warwick.
In a paper published in Nature Energy,
Dr Ross Hatton, Professor Richard Walton and colleagues, explain how
solar cells could be produced with tin, making them more adaptable and
simpler to produce than their current counterparts.
Solar cells based on a class of semiconductors known as lead
perovskites are rapidly emerging as an efficient way to convert sunlight
directly into electricity. However, the reliance on lead is a serious
barrier to commercialisation, due to the well-known toxicity of lead.
Dr Ross Hatton and colleagues show that perovskites using tin in
place of lead are much more stable than previously thought, and so could
prove to be a viable alternative to lead perovskites for solar cells.
Lead-free cells could render solar power cheaper, safer and more commercially attractive - leading to it becoming a more prevalent source of energy in everyday life.
This could lead to a more widespread use of solar power, with
potential uses in products such as laptop computers, mobile phones and
cars.
The team have also shown how the device structure can be greatly
simplified without compromising performance, which offers the important
advantage of reduced fabrication cost.
Dr Hatton comments that there is an ever-pressing need to develop renewable sources of energy:
"It is hoped that this work will help to stimulate an intensive
international research effort into lead-free perovskite solar cells,
like that which has resulted in the astonishingly rapid advancement of lead perovskite solar cells.
"There is now an urgent need to tackle the threat of climate change
resulting from humanity's over reliance on fossil fuel, and the rapid
development of new solar technologies must be part of the plan."
Perovskite solar cells are lightweight and compatible with flexible
substrates, so could be applied more widely than the rigid flat plate
silicon solar cells that currently dominate the photovoltaics market, particularly in consumer electronics and transportation applications.
The paper, 'Enhanced Stability and Efficiency in Hole-Transport Layer Free CsSnI3 Perovskite Photovoltaics', is published in Nature Energy,
and is authored by Dr Ross Hatton, Professor Richard Walton and PhD
student Kenny Marshall in the Department of Chemistry, along with Dr
Marc Walker in the Department of Physics.
A microscopic image of 2.5 billion-year-old sulfur-oxidizing
bacterium. Credit: Andrew Czaja, UC assistant professor of geology
Somewhere between Earth's creation and
where we are today, scientists have demonstrated that some early life
forms existed just fine without any oxygen.
While
researchers proclaim the first half of our 4.5 billion-year-old planet's
life as an important time for the development and evolution of early
bacteria, evidence for these life forms remains sparse including how
they survived at a time when oxygen levels in the atmosphere were less
than one-thousandth of one percent of what they are today.
Recent geology research from the University of Cincinnati presents
new evidence for bacteria found fossilized in two separate locations in
the Northern Cape Province of South Africa.
"These are the oldest reported fossil sulfur bacteria to date," says
Andrew Czaja, UC assistant professor of geology. "And this discovery is
helping us reveal a diversity of life and ecosystems that existed just
prior to the Great Oxidation Event, a time of major atmospheric
evolution."
The 2.52 billion-year-old sulfur-oxidizing bacteria are described by
Czaja as exceptionally large, spherical-shaped, smooth-walled
microscopic structures much larger than most modern bacteria, but
similar to some modern single-celled organisms that live in deepwater
sulfur-rich ocean settings today, where even now there are almost no
traces of oxygen.
UC Professor Andrew Czaja indicates the layer of rock from which
fossil bacteria were collected on a 2014 field excursion near the town
of Kuruman in the Northern Cape Province of South Africa. Credit: Aaron
Satkoski, UWM postdoc on the excursion.
In his research published in the December issue of the journal Geology
of the Geological Society of America, Czaja and his colleagues Nicolas
Beukes from the University of Johannesburg and Jeffrey Osterhout, a
recently graduated master's student from UC's department of geology,
reveal samples of bacteria that were abundant in deep water areas of the
ocean in a geologic time known as the Neoarchean Eon (2.8 to 2.5
billion years ago).
"These fossils represent the oldest known organisms that lived in a
very dark, deep-water environment," says Czaja. "These bacteria existed
two billion years before plants and trees, which evolved about 450
million years ago. We discovered these microfossils preserved in a layer
of hard silica-rich rock called chert located within the Kaapvaal
craton of South Africa."
With an atmosphere of much less than one percent oxygen, scientists
have presumed that there were things living in deep water in the mud
that didn't need sunlight or oxygen, but Czaja says experts didn't have
any direct evidence for them until now.
Czaja argues that finding rocks this old is rare, so researchers'
understanding of the Neoarchean Eon are based on samples from only a
handful of geographic areas, such as this region of South Africa and
another in Western Australia.
According to Czaja, scientists through the years have theorized that
South Africa and Western Australia were once part of an ancient
supercontinent called Vaalbara, before a shifting and upending of
tectonic plates split them during a major change in the Earth's surface.
Based on radiometric dating and geochemical isotope analysis, Czaja
characterizes his fossils as having formed in this early Vaalbara
supercontinent in an ancient deep seabed containing sulfate from
continental rock. According to this dating, Czaja's fossil bacteria were
also thriving just before the era when other shallow-water bacteria
began creating more and more oxygen as a byproduct of photosynthesis.
"We refer to this period as the Great Oxidation Event that took place 2.4 to 2.2 billion years ago," says Czaja.
Microstructures here have physical characteristics consistent
with the remains of compressed coccodial (round) bacteria
microorganisms. Credit: Andrew Czaja, permission to publish by
Geological Society of America
Early recycling
Czaja's fossils show the Neoarchean bacteria in plentiful numbers
while living deep in the sediment. He contends that these early bacteria
were busy ingesting volcanic hydrogen sulfide—the molecule known to
give off a rotten egg smell—then emitting sulfate, a gas that has no
smell. He says this is the same process that goes on today as modern
bacteria recycle decaying organic matter into minerals and gases.
"The waste product from one [bacteria] was food for the other," adds Czaja.
"While I can't claim that these early bacteria are the same ones we
have today, we surmise that they may have been doing the same thing as
some of our current bacteria," says Czaja. "These early bacteria likely
consumed the molecules dissolved from sulfur-rich minerals that came
from land rocks that had eroded and washed out to sea, or from the
volcanic remains on the ocean's floor.
There is an ongoing debate about when sulfur-oxidizing bacteria arose
and how that fits into the earth's evolution of life, Czaja adds. "But
these fossils tell us that sulfur-oxidizing bacteria were there 2.52 billion years ago, and they were doing something remarkable."
New research led by Washington University School of Medicine in
St. Louis shows that patients with acute myeloid leukemia (AML) whose
cancer cells carry TP53 mutations -- a feature that correlates with an
extremely poor prognosis -- may live longer if they are treated with
decitabine, a less intensive chemotherapy drug. The study's first
author, John Welch, M.D., PhD, is pictured with Phillip Houghton, who is
being treated for AML. Credit: Washington University
Patients with the most lethal form of acute
myeloid leukemia (AML) - based on genetic profiles of their cancers -
typically survive for only four to six months after diagnosis, even with
aggressive chemotherapy. But new research indicates that such patients,
paradoxically, may live longer if they receive a milder chemotherapy
drug.
Treatment with the less intensive drug, decitabine, is not a cure. But surprisingly, AML patients whose leukemia cells carried mutations in a nefarious cancer gene called TP53 consistently achieved remission after treatment with decitabine. Their median survival was just over a year.
The study, by a team of scientists at Washington University School of Medicine in St. Louis, is published Nov. 24 in The New England Journal of Medicine.
In AML, treatment involves intensive chemotherapy to try to kill the
patient's leukemia cells and put the cancer into remission. If
successful, a follow-up bone-marrow transplant can offer a possible
cure, but this course of treatment is recommended only for patients with
a high risk of relapse because the procedure can cause severe
complications, even death.
"What's really unique here is that all the patients in the study with
TP53 mutations had a response to decitabine and achieved an initial
remission," said the study's senior author, Timothy J. Ley, MD, the
Lewis T. and Rosalind B. Apple Professor of Medicine, noting that in
AML, TP53 mutations have been correlated with an extremely poor
prognosis. "With standard aggressive chemotherapy, we only see about 20
to 30 percent of these patients achieving remission, which is the
critical first step to have a chance to cure patients with additional
therapies.
"The findings need to be validated in a larger trial," Ley added,
"but they do suggest that TP53 mutations can reliably predict responses
to decitabine, potentially prolonging survival in this ultra high-risk
group of patients and providing a bridge to transplantation in some
patients who might not otherwise be candidates."
In an accompanying editorial, Elihu Estey, MD, an AML expert at the
University of Washington Medical Center and Fred Hutchinson Cancer
Research Center in Seattle, noted that AML is not one disease but many,
each driven by different genetic mutations. The results of the current
trial, he said, point to the inevitable need to replace large cancer
clinical trials evaluating homogeneous drug treatments with smaller
trials that involve subgroups of patients, with treatments targeted to
their specific mutations.
The current study involved 116 patients treated with decitabine at
the Siteman Cancer Center at Washington University School of Medicine
and Barnes-Jewish Hospital, and at the University of Chicago. The
patients either had AML - a cancer of the bone marrow - or
myelodysplastic syndrome (MDS), a group of blood cancers that often
progresses to AML. This year, an estimated 20,000 people living in the
U.S. will be diagnosed with AML, and at least 11,000 deaths will be
attributed to the disease.
Decitabine often is given to older patients
with AML or MDS because it is less toxic than standard chemotherapies.
But fewer than half of patients who get the drug achieve an initial
remission, so the researchers wanted to determine whether specific
mutations in the patients' cancer cells could predict their responses to treatment.
To find out, they sequenced all the genes in patients' cancer cells
or analyzed select cancer genes. They also conducted standard tests to
look for broken, missing or rearranged chromosomes. Then, the
researchers correlated these molecular markers with treatment response
to identify subgroups of patients likely to benefit from decitabine.
Among the patients in the study, 46 percent achieved a remission with
decitabine. But, remarkably, all 21 patients whose leukemia cells
carried TP53 mutations went into remission.
Patients also were likely to respond to decitabine if they were
deemed to have an "unfavorable risk" prognosis based on extensive
chromosomal rearrangements in their cancer cells; many of these patients
also had TP53 mutations. Indeed, 66 percent of patients with an
unfavorable risk achieved remission, compared with 34 percent of
patients who had more favorable prognoses.
"The challenge with using decitabine has been knowing which patients
are most likely to respond," said co-author Amanda Cashen, MD, an
associate professor of medicine who led an earlier clinical trial of
decitabine in older patients with AML. "The value of this study is the
comprehensive mutational analysis that helps us figure out which
patients are likely to benefit. This information opens the door to using
decitabine in a more targeted fashion to treat not just older patients,
but also younger patients who carry TP53 mutations."
First author John Welch, MD, PhD, an assistant professor of medicine,
added: "It's important to note that patients with an extremely poor
prognosis in this relatively small study had the same survival outcomes
as patients facing a better prognosis, which is encouraging. We don't
yet understand why patients with TP53 mutations consistently respond to
decitabine, and more work is needed to understand that phenomenon."
Responses to decitabine are usually short-lived, however, with
remissions typically lasting for about a year. Decitabine does not
completely clear all the leukemia cells that carry TP53 mutations, and
these cells invariably become resistant to the drug, leading to relapse.
"Remissions with decitabine typically don't last long, and no one was
cured with this drug," Ley explained. "But patients who responded to
decitabine live longer than what you would expect with aggressive
chemotherapy, and that can mean something. Some people live a year or
two and with a good quality of life, because the chemotherapy is not too
toxic."
Roughly 10 percent of AML patients carry TP53 mutations in their
leukemia cells. Among patients in the study with such mutations, median
survival was 12.7 months - which is not significantly different from the
15.4 months' survival seen in patients without the mutations - and is
longer than the typical four- to six-month survival observed in such
patients treated with more aggressive therapies.
Decitabine was approved by the FDA in 2006 as a treatment for MDS,
but oncologists often prescribe it off-label as a treatment for AML,
particularly in older patients. AML typically strikes in a person's
mid-60s; the average age of people in the current study was 74.
"We're now planning a larger trial to evaluate decitabine in AML
patients of all ages who carry TP53 mutations," Welch said. "It's
exciting to think we may have a therapy that has the potential to
improve response rates in this group of high-risk patients."
Cannabinoids and memory
Few classes of drugs have
galvanized the pharmaceutical industry in recent times like the
cannabinoids. This class of molecules includes not only the natural
forms, but also a vast new treasury of powerful synthetic analogs with
up to several hundred times the potency as measured by receptor activity
and binding affinity. With the FDA now fast tracking all manner of
injectables, topicals, and sprays promising everything from relief of
nebulous cancer pain to anti-seizure neuroprotection, more than a few
skeptics have been generated.
What inquiring
minds really want to know, beyond the thorny issue of how well they
actually work, is how do they work at all? If you want to understand
what something is doing in the cell, one useful approach is to ask what
it does to their mitochondria.
With drug companies now drooling over the possibility of targeting
drugs and treatments directly to these organelles by attaching
mitochondrial localization sequences (MLS) or other handler molecules,
answers to this kind of question are now coming into focus.
But even with satisfactory explanations in hand, there would still be
one large hurdle standing in the way of cannabinoid medical bliss:
Namely, even if a patient can manage to avoid operating vehicles or
heavy machinery throughout the course of their treatment, how do they
cope with the endemic collateral memory loss these drugs invariably
cause?
A recent paper published in Nature neatly ties all these
subtleties together, and even suggests a possible way out of the brain
fog by toggling the sites of cannabinoid action between mitochondria and
other cellular compartments. By generating a panel of cannabinoid
receptor and second messenger molecules with and without the appropriate
MLS tags or accessory binding proteins, the authors were able to
directly link cannabinoid-controlled mitochondrial activity to memory
formation.
One confounder in this line of work is that these MLSs are very
fickle beasts. The 22 or so leader amino acids that make up their 'code'
is not a direct addresses in any sense. While the consensus sequences
that localize protease action or sort nuclear, endoplasmic reticulum,
and plasma membrane proteins generally contain clearly recognizable
motifs, any regularities in the MLSs have only proven visible to a
computer. That is not to say that MLSs are fictions—they clearly do
work—but their predictable action is only witnessed whole once their
3-dimensional vibrating structures are fully-conformed.
The authors availed themselves of two fairly sophisticated programs
called Mitoprot and PSQRT to remove any guesswork in identifying a
potential MLS in CN1 cannabinoid receptors. CN1s had been previously
associated by immunohistochemical methods to what we might call the
mitochondrial penumbra, but their presence there may have been purely
incidental. This in silico analysis theoretically confirmed the presence
of a putative MLS in CB1 and encouraged them to carry out further
manipulations of this pathway.
Namely, the researchers took a mouse with the mitochondrial mtCB1
receptor knocked out, and then added modified versions back using viral
vectors. When they applied the synthetic cannabinoid ligands (known as
WIN55,212 and HU210 ) they found that mitochondrial respiration and
mobility, and subsequently memory formation, remained largely intact in
animals without the MLS in their receptor.
The researchers were then able to look further downstream using the
same general strategy of controlling localization of the second
messenger molecule protein kinase A (PKA). By fusing a constitutively
active mutant form of PKA to an MLS and putting it inside using an
adenovirus they were able to trace the signal cascade into the heart of
the complex I of the respiratory chain.
The presence and origin of full G-protein receptor signal pathways in
mitochondria is now more than just an academic question. Exactly how
retroviruses and other molecular agents of sequence modification managed
to re-jigger gene duplicated backups of proteins like CN1 to add
alternatively spliced MLS tags is still shrouded in mystery.
Our ability to now harness these same slow evolutionary processes in
real time, and bend them to our needs, will undoubtedly have implication
well beyond the cannabinoid market. Together the results above suggest
the tantalizing possibility of preserving some of the desired benefits
of cannabinoids while eliminating the unintended consequences like memory loss or full blown amnesia.
A bridge that bends in an strong earthquake and not only remains
standing, but remains usable is making its debut in its first real-world
application as part of a new exit bridge ramp on a busy downtown
Seattle highway.
"We've
tested new materials, memory retaining metal rods and flexible concrete
composites, in a number of bridge model studies in our large-scale
shake table lab, it's gratifying to see the new technology
applied for the first time in an important setting in a seismically
active area with heavy traffic loads," Saiid Saiidi, civil engineering
professor and researcher at the University of Nevada, Reno, said. "Using
these materials substantially reduces damage and allows the bridge to
remain open even after a strong earthquake."
Saiidi, who pioneered this technology, has built and destroyed, in
the lab, several large-scale 200-ton bridges, single bridge columns and
concrete abutments using various combinations of innovative materials,
replacements for the standard steel rebar and concrete materials and
design in his quest for a safer, more resilient infrastructure.
"We have solved the problem of survivability, we can keep a bridge usable after a strong earthquake," Saiidi said. "With these techniques and materials, we will usher in a new era of super earthquake-resilient structures."
The University partnered with the Washington Department of
Transportation and the Federal Highway Administration to implement this
new technology on their massive Alaska Way Viaduct Replacement Program,
the centerpiece of which is a two-mile long tunnel, but includes 31
separate projects that began in 2007 along the State Route 99 corridor
through downtown Seattle.
"This is potentially a giant leap forward," Tom Baker, bridge and
structures engineer for the Washington State Department of
Transportation, said. "We design for no-collapse, but in the future, we
could be designing for no-damage and be able to keep bridges open to
emergency vehicles, commerce and the public after a strong quake."
Modern bridges are designed to not collapse during an earthquake, and
this new technology takes that design a step further. In the earthquake
lab tests, bridge columns built using memory-retaining nickel/titanium
rods and a flexible concrete composite returned to their original shape
after an earthquake as strong as a magnitude 7.5.
"The tests we've conducted on 4-span bridges leading to this point
aren't possible anywhere else in the world than our large-scale
structures and earthquake engineering lab," Saiidi said. "We've had
great support along the way from many state highway departments and
funding agencies like the National Science Foundation, the Federal
Highway Administration and the U.S. Department of Transportation.
Washington DOT recognized the potential of this technology and
understands the need to keep infrastructure operating following a large
earthquake."
In an experiment in 2015, featured in a video, one of Saiidi's bridge's
moved more than six inches off center at the base and returned to its
original position, as designed, in an upright and stable position. Using
the computer-controlled hydraulics, the earthquake engineering lab can
increase the intensity of the recorded earthquake. Saiidi turned the dial up to 250 percent of the design parameters and still had excellent results.
"It had an incredible 9 percent drift with little damage," Saiidi said.
The Seattle off-ramp with the innovative columns is currently under
construction and scheduled for completion in spring 2017. After the new
SR 99 tunnel opens, this ramp, just south of the tunnel entrance, will
take northbound drivers from SR 99 to Seattle's SODO neighborhood.
A new WSDOT video describes how this innovative technology works.
"Dr. Saiidi sets the mark for the level of excellence to which the
College of Engineering aspires," Manos Maragakis, dean of the
University's College of Engineering, said. "His research is original and
innovative and has made a seminal contribution to seismic safety around
the globe."
Jedd Wolchok is the Director of the Ludwig Collaborative
Laboratory at Memorial Sloan Kettering Cancer Center. Credit: Ludwig
Cancer Research
A Ludwig Cancer Research study shows that
an experimental drug currently in clinical trials can reverse the
effects of troublesome cells that prevent the body's immune system from
attacking tumors. The researchers also establish that it is these
suppressive cells that interfere with the efficacy of immune checkpoint
inhibitors. This class of immunotherapies lifts the brakes that the body
imposes on the immune system's T cells to unleash an attack on cancer
cells.
"Though
checkpoint inhibitors have durable effects when they work, not all
patients respond to the treatment," says Taha Merghoub, an investigator
at the Ludwig Memorial Sloan Kettering Collaborative Laboratory who led
the study with Director Jedd Wolchok. "Part of the reason for this is
that some tumors harbor tumor-associated myeloid cells, or TAMCs, that prevent T cells from attacking tumor cells."
In a study published online today in Nature, Merghoub and his
team used mouse models of cancer to show that the effects of TAMCs can
be reversed by an appropriately targeted therapy.
To show that TAMCs were indeed involved in resistance to checkpoint
blockade, the researchers used a specific growth stimulant to increase
their number in melanoma tumors to create a suitable model for their
studies. They found that this made the tumors less susceptible to
checkpoint blockade.
"We were able to make a tumor that was not rich in immune suppressing myeloid cells into one that was," says Merghoub.
Having established a link between TAMCs and checkpoint inhibitor
resistance, the researchers next set out to test the hypothesis that
blocking immune suppressor cell activity would improve immunotherapy
response. To do this, they used an experimental drug manufactured by
Infinity Pharmaceuticals called IPI-549. The drug, which is available
for clinical use, blocks a molecule in the suppressor cells
called PI3 kinase-gamma. Blocking this molecule changes the balance of
these immune suppressor cells in favor of more immune activation.
"We effectively reprogrammed the TAMCs, turning them from bad guys into good guys," Merghoub said.
IPI-549 dramatically improved responses to immune checkpoint blockade
(ICB) therapy for tumors with high concentrations of TAMCs. When
checkpoint inhibitors were administered to mice with suppressed tumors,
only 20% of the animals underwent complete remission. When the same
drugs were administered with IPI-549, that number jumped to 80%. IPI-549
provided no benefit to tumors lacking the suppressor cells.
Merghoub and his team also showed that tumors that were initially
sensitive to checkpoint inhibitors were rendered unresponsive when their
TAMC concentrations were boosted with growth stimulants.
Taken together, these results indicate that TAMCs promote resistance
to checkpoint inhibitors and that IPI-549 can selectively block these
cells, thereby overcoming their resistance.
Merghoub said the findings help pave the way for a precision medicine
approach to immunotherapy that will allow cancer treatments to be
tailored to a patient's particular tumor profile. "We can now
potentially identify patients whose tumors possess immune suppressor
cells and add a drug to their treatment regimen to specifically disarm
them," he added.
IPI-549 is currently undergoing a Phase I trial in the United States
to assess its safety when administered alone and in combination with the
FDA-approved checkpoint inhibitor drug nivolumab (Opdivo).
Virtual reality technology has you thinking you are
doing many things, but there is much uncharted territory in eating
virtually.
Imagine
what the tourism industry could do with VR technology extending sensory
stimulation beyond the eyes and ears. Imagine inviting prospective
restaurant clients in virtual reality mode to the meat, fish and chicken
specialties, pizza or chocolate cakes. Imagine any number of
applications where the sensory experience in virtual reality expands.
Scientists are focusing on VR technology that can fool you into
thinking you are tasting food that is not of course really there.
Researchers from Singapore and another team from Japan have their own
studies that explore the realm of tasting and even chewing.
Vlad Dudau, Neowin, said these explorers managed to replicate the tastes and textures of different foods.
A recent conference in Japan on user interface was given much "food" tech for thought.
The work titled "Virtual Sweet: Simulating Sweet Sensation Using
Thermal Stimulation on the Tip of the Tongue," explored what it is like
to be tasting sweet food virtually.
"Being a pleasurable sensation, sweetness is recognized as the most
preferred sensation among the five primary taste sensations. In this
paper, we present a novel method to virtually simulate the sensation of sweetness by applying thermal stimulation to the tip of the human tongue.
To digitally simulate the sensation of sweetness, the system delivers
rapid heating and cooling stimuli to the tongue via a 2x2 grid of
Peltier elements. To achieve distinct, controlled, and synchronized
temperature variations in the stimuli, a control module is used to
regulate each of the Peltier elements. Results from our preliminary
experiments suggest that the participants were able to perceive mild
sweetness on the tip of their tongue while using the proposed system."
Nimesha Ranasinghe and Ellen Yi-Luen Do of the National University of
Singapore are the two explorers. This is a device where changes in
temperature serve to mimic the sensation of sweetness on the tongue.
Victoria Turk in New Scientist wrote about what their
technology does: "The user places the tip of their tongue on a square of
thermoelectric elements that are rapidly heated or cooled, hijacking thermally sensitive neurons that normally contribute to the sensory code for taste."
MailOnline described it as a "virtual sweetness instrument"
which makes use of "a grid of four elements which generate temperature
changes of 5°C in a few seconds. "When applied to the tip of the tongue,
said the report, "the temperature change results in a virtual sweet
sensation." A 9V battery is put to use. Results: Out of 15 people, eight
registered a very mild sweet taste, said MailOnline.
Applications could include a taste-enhancing technology for dieters. Dr Ranashinghe told MailOnline:
'We believe this will especially helpful for the people on restricted
diets for example salt (hypertension and heart problems) and sugar
(diabetics)." New Scientist said Ranasinghe and Do could see a system like this embedded in a glass or mug to make low sugar drinks taste sweeter.
Another group from the University of Tokyo is using electrodes to
stimulate the jaw muscles. Tokyo Researchers Arinobu Niijima and
Takefumi Ogawa are reporting results from an electrical muscle
stimulation (EMS) test of jaw movements in chewing.
"We propose Electric Food Texture System, which can present virtual
food texture such as hardness and elasticity by electrical muscle
stimulation (EMS) to the masseter muscle," said the researchers in a
video posted last month on their work, "Study on Control Method of
Virtual Food Texture by Electrical Muscle Stimulation."
Dudau in Neowin described their experiment, where "scientists
attached electrodes to jaw muscles and managed to simulate the sensation
of biting into different materials. For example, by varying the
electrical stimulation, users reported that while eating a real cookie,
it felt like biting into something soft, or chewing something hard
alternatively."
Turk in New Scientist also talked about the Tokyo team who
presented "a device that uses electricity to simulate the experience of
chewing foods of different textures. Arinobu Niijima and Takefumi
Ogawa's Electric Food Texture System also uses electrodes, but not on
the tongue, instead they place them on the masseter muscle – a muscle in
the jaw used for chewing – to give sensations of hardness or chewiness
as a user bites down. 'There is no food in the mouth, but users feel as
if they are chewing some food due to haptic feedback by electrical
muscle stimulation,' says Niijima."
Getting into technical details, MailOnline said "By delivering
short pulses of between 100 to 250 Hz they were able to stimulate the
masseter muscles, used to chew solid foods."
So if the 'sugar' researchers were looking at taste sensation, these
researchers were looking at food texture. They said, "In this paper, we
investigated the feasibility to control virtual food texture by EMS."
The researchers said on their video page, "We conducted an experiment
to reveal the relationship of the parameters of EMS and those of
virtual food texture. The experimental results show that the higher
strength of EMS is, the harder virtual food texture is, and the longer
duration of EMS is, the more elastic virtual food texture is."
If at higher frequency, the sensation was that of eating tougher,
chewy food but a longer pulse simulated a more elastic texture.
(Phys.org)—The change point problem is a
concept in statistics that pops up in a wide variety of real-world
situations, from stock markets to protein folding. The idea is to detect
the exact point at which a sudden change has occurred, which could
indicate, for example, the trigger of a financial crisis or a misfolded
protein step.
Now in a new paper published in Physical Review Letters, physicists Gael Sentís et al. have taken the change point problem to the quantum domain.
"Our work sets an important landmark in quantum information theory
by porting a fundamental tool of classical statistical analysis into a
fully quantum setup," Sentis, at the University of the Basque Country in
Bilbao, Spain, told Phys.org.
"With an ever-growing number of promising applications of quantum
technologies in all sorts of data processing, building a quantum
statistical toolbox capable of dealing with real-world practical issues,
of which change point detection is a prominent example, will be
crucial. In our paper, we demonstrate the working principles of quantum
change point detection and facilitate the grounds for further research
on change points in applied scenarios."
Although change point problems can deal with very complex situations,
they can also be understood with the simple example of playing a game
of Heads or Tails. This game begins with a fair coin, but at some
unknown point in the game the coin is switched with a biased one. By
statistically analyzing the results of each coin toss from the
beginning, it's possible to determine the most likely point at which the
coin was switched.
Extending this problem to the quantum realm, the physicists looked at
a quantum device that emits particles in a certain state, but at some
unknown point the source begins to emit particles in a different state.
Here the quantum change point problem can be understood as a problem of quantum state
discrimination, since determining when the change in the source
occurred is the same as distinguishing among all possible sequences of
quantum states of the emitted particles.
Physicists can determine the change point in this situation in two
different ways: either by measuring the state of each particle as soon
as it arrives at the detector (a "local measurement"), or by waiting
until all of the particles have reached the detector and making a
measurement at the very end (a "global measurement").
Although the local measurement method sounds appealing because it can
potentially detect the change point as soon as it occurs without
waiting for all of the particles to be emitted, the researchers found
that global measurements outperform even the best local measurement
strategies.
The "catch" is that global measurements are more difficult to experimentally realize and require a quantum memory
to store the quantum states as they arrive at the detector one by one.
The local measurement methods don't require a quantum memory, and
instead can be implemented using much simpler devices in sequence. Since
global detection requires a quantum memory, the results show that
change point detection is another of the many problems for which quantum
methods outperform all classical ones.
"We expected that global measurements
would help, as coherent quantum operations tend to exploit genuinely
quantum resources and generally outperform local operations in many
information processing tasks," Sentis said. "However, this is a
case-dependent advantage, and sometimes sophisticated and clever local
strategies are enough to cover the gap. The fact that here there is a
finite performance gap says something fundamental about change point
detection in quantum scenarios."
The results have potential applications in any situation that
involves analyzing data collected over time. Change point detection is
also often used to divide a data sample into subsamples that can then be
analyzed individually.
"The ability to accurately detect quantum change points has immediate
impact on any process that requires careful control of quantum
information," Sentis said. "It can be considered a quality testing
device for any information processing task that requires (or produces) a
sequence of identical quantum states. Applications may range from
probing quantum optical fibers to boundary detection in solid state
systems."
In the future, the researchers plan on exploring the many applications of quantum change point detection.
"We plan on extending our theoretical methods to deal with more
realistic scenarios," Sentis said. "The possibilities are countless. A
few examples of generalizations we are exploring are multiple change
points, noisy quantum states, and detection of change points in optical
setups."
Researchers at the University of Illinois
at Chicago have identified a new way to block the action of genetic
mutations found in nearly 30 percent of all cancers.
Mutations in
genes for the RAS family of proteins are present in nearly 90 percent of
pancreatic cancers and are also highly prevalent in colon cancer, lung
cancer and melanoma, the most dangerous kind of skin cancer.
The group of proteins include three members, K-RAS, H-RAS and N-RAS.
The prevalence of RAS mutations in human cancers and the dependence
of tumors on RAS for survival has made a RAS a prime target for cancer
research and drug discovery. Scientists and drug developers have long
studied RAS oncogenes hoping to find a new treatment for cancer, but
they have not yet been able to identify drugs that safely inhibit the
oncogene's activity.
John O'Bryan, associate professor of pharmacology in the UIC College
of Medicine, led a team of researchers that took a different approach to
studying RAS, and discovered that a synthetic binding protein they call
"NS1 monobody," which they created in the lab, can block the activity
of the RAS proteins.
"We did not look for a drug or specifically for an inhibitor," said
O'Bryan, who is also a member of the University of Illinois Cancer
Center and holds an appointment at the Jesse Brown VA Medical Center in
Chicago. "We used monobody technology, a type of protein-engineering
technology, to identify regions of RAS that are critical for its
function."
Unlike conventional antibodies, monobodies are not dependent on their
environment and can be readily used as genetically encoded inhibitors,
O'Bryan said.
"The beauty of the technology is that when a monobody binds a
protein, it usually works as an inhibitor of that protein," he said.
Monobodies were developed by Shohei Koide, a co-author on the study
who is professor of biochemistry and molecular pharmacology at New York
University. They have been used to target a diverse array of proteins
that include enzymes and receptors.
The researchers found that the NS1 monobody binds to an area of the
RAS protein molecule that was not previously known to be important for
its oncogenic activity. NS1 strongly inhibits oncogenic K-RAS and H-RAS
function by blocking the ability of the protein to interact with an
identical one to form a molecular pair. NS1 does not affect N-RAS.
O'Bryan says the findings, published in the journal Nature Chemical Biology,
provide important insight into long-standing questions about how RAS
proteins function in cells. These insights may help guide the
development of new therapeutic approaches to treating cancer by
interfering with mutant RAS function in cancer cells.
"Development of effective RAS inhibitors represents a 'holy grail' in
cancer biology," O'Bryan said. "We now have a powerful tool we can use
to further probe RAS function. While future studies and trials are
needed before these findings can be leveraged outside the lab, this
study provides new insight into how we can potentially inhibit RAS to
slow tumor growth."
Rice University’s low-cost, open-source Light Plate Apparatus
can easily be used by nonengineers and noncomputer programmers and can
be assembled by a nonexpert in one day from components costing less than
$150. Credit: Jeff Fitlow/Rice University
Nobody likes a cheater, but Rice University
bioengineering graduate student Karl Gerhardt wants people to copy his
answers. That's the whole point.
Gerhardt and Rice colleagues have created the first low-cost, easy-to-use optogenetics
hardware platform that biologists who have little or no training in
engineering or software design can use to incorporate optogenetics
testing in their labs.
Rice's Light Plate Apparatus (LPA) is described in a paper available for free online this week in the open-access journal Scientific Reports.
The LPA, which was created in the lab of Jeffrey Tabor, assistant
professor of bioengineering, uses open-source hardware and software. The
apparatus can deliver two independent light signals to each well in a
standard 24-well plate and has sockets that accept LEDs of wavelengths
ranging from blue to far red. Total component costs for the LPA are less
than $400—$150 for labs with a 3-D printer—and each unit can be
assembled and calibrated by a nonexpert in one day.
"Our intent is to bring optogenetics to any researcher interested in
using it," said Tabor, whose students created the LPA. In doing so, they
found ways to make most of its parts with 3-D printers and also created
software called Iris that uses simple buttons and pull-down menus to
allow researchers to program the instrument for a wide range of
experiments.
Rice bioengineers Karl Gerhardt (left) and Jeffrey Tabor with
the Light Plate Apparatus, a low-cost, open-source optogenetics
platform. Credit: Jeff Fitlow/Rice University
Optogenetics, which was developed in the
past 15 years, involves genetically modifying cells with light-sensing
molecules so that light can be used to turn genes and other cellular
processes on or off. Its most notable successes have come in
neuroscience following the invention of brain-implantable optical neuro
interfaces, which have explored the cells and mechanisms associated with
aggression, parenting, drug addiction, mating, same-sex attraction,
anxiety, obsessive-compulsive disorders and more.
"Over the past 5-10 years, practically every biological process has
been put under optogenetics control," said Gerhardt, who works in
Tabor's lab. "The problem is that while everyone has been developing the
biological tools to do optogenetics—the light-sensing proteins,
gene-expression systems, protein interactions, etc.—outside of
neuroscience, no one has really developed good hardware that makes it
easy to use those tools."
To demonstrate the broad applicability of LPA, Tabor, Gerhardt and
co-authors used the system to perform a series of optogenetics tests on a
diverse set of model organisms, including gut bacteria, yeast,
mammalian cells and photosynthetic cyanobacteria.
Gerhardt didn't come to Rice intending to invent the world's first
easy-to-use optogenetics research platform. A biochemist by training, he
initially was interested in simply creating something that would allow
him to incorporate optogenetics in his own research. In early 2014,
Gerhardt was studying the social amoeba Dictyostelium discoideum. Evan
Olson, another Ph.D. student in Tabor's group, had just created the
"light tube array," or LTA, an automated system for doing optogenetics
on up to 64 test tubes at a time.
Unfortunately for Gerhardt, D. discoideum,
which biologists commonly call "dicty," prefers to grow on flat
surfaces, like Petri dishes and flat-bottomed well plates. Dicty is also
sensitive to vibrations and movement. Like dicty, many organisms
commonly studied in biology labs, including many animal cell lines and
virtually all human cells, require similar conditions.
"I couldn't culture dicty in the LTA, so I built a sort of
plate-based version, and I used it for a couple of experiments, but it
didn't work very well," Gerhardt said. "Then, some other people in our
lab who had training in electrical engineering and Evan, with his
physics background, said, 'We can take this version and make it a lot
better.'"
Gerhardt said the group kept innovating and coming up with new
versions of the hardware. For example, to make it easy to change the
wavelength of light, the team incorporated standard sockets so it would
be easy to swap out different colored LEDs. They also added a low-cost
microcontroller with an SD card reader, drivers capable of producing
more than 4,000 levels of light intensity and millisecond time control.
"We got more and more ambitious in terms of the features we wanted to
add, and now we're on version three or four of the hardware," he said.
"Then Lucas (Hartsough), Brian (Landry) and Felix (Ekness), members of
our group who had expertise in programming and website design, said,
'We'll make the software,' and that's where Iris came from."
Rice University graduate student Sebastián Castillo-Hair
conducts tests with the Light Plate Apparatus, an open-source
optogenetics research platform developed in the laboratory of Rice’s
Jeffrey Tabor, assistant professor of bioengineering. Credit: Jeff
Fitlow/Rice University
Iris makes use of a graphical user
interface to allow people without specialized computer training to
easily program experiments for the LPA.
"Programming is a major barrier for some biologists who want to work
with this kind of hardware," Gerhardt said. "Optogenetics hardware, most
of the time, requires someone with programming experience who can go
into the command line and write code. We wanted to eliminate that
barrier."
To simplify the process for getting started with LPA, Tabor and
Gerhardt have published all the software, design files and
specifications for the system on GitHub, a site that caters to the
do-it-yourself community by making it easy to create, share and
distinguish different versions of software and files for open-source
platforms like LPA.
Gerhardt said at least a half-dozen research groups began making LPAs
after an early version of the paper was posted on a biology preprint
server, and he hopes many more begin using it now that the Scientific Reports paper has been published.
"I hope this becomes the standard format for doing general
optogenetics experiments, especially for people on the biology end of
the spectrum who would never think about building their own hardware,"
Gerhardt said. "I hope they'll see this and say, 'OK. We can do
optogenetics now.'"